



18th April 2023

dorsaVi signs new contract with University of Rochester Medical Center

Key highlights

- **dorsaVi has agreed to commence a new project with a leading U.S. University, University of Rochester Medical Center**
- **The agreement will generate ~A\$100,000¹ in sponsored research support over an initial 12-month period, with potential to extend the project for up to 5 years**
- **dorsaVi will leverage its leading wearable sensor technology coupled with UR Medicine Motion Laboratory's new state of the art gait and motion lab to investigate spinal motion and patterns of movement**
- **The project will be led by Assistant Professor and Director of the University of Rochester Medical Center, Ram Haddas, who is also executive committee member of the North American Spine Society**
- **The new agreement will support research on dorsaVi's product line, while enhancing its top-tier client base and diversifying its revenue stream**

Melbourne, Australia, 18th April 2023: dorsaVi (ASX:DVL) (dorsaVi or the Company), a leading provider of wearable sensor technology is pleased to announce it has signed a new contract with the University of Rochester Medical Center, a foremost U.S. university and academic medical center. The contract will initially generate ~A\$100,000¹ in sponsored research support over a 12-month period, with the potential to extend the agreement for up to 5 years.

dorsaVi and the University of Rochester Medical Center will collaborate to research and investigate spinal motion and patterns of movement. The study will rely on dorsaVi's wearable sensor technology and advanced AI and Machine Learning algorithms along with UR Medicine Motion Laboratory's brand-new, state of the art gait and motion lab to drive greater insights into patient movement.

The study is to be led by the Assistant Professor of Orthopedics and Director of the UR Medicine Motion Laboratories at the University of Rochester Medical Center. Dr. Haddas has extensive experience in Clinical Biomechanics, Kinesiology, Rehabilitation Sciences, Healthcare Engineering, and Wearables. Dr. Haddas received his Ph.D. in Rehabilitation Science from Texas Tech University Health Sciences Center and holds an MBA from The University of Texas. Dr. Haddas has received multiple international and national awards for his research work. Moreover, a world-renowned and innovative method he developed allows patients' balance and compensation to be quantified using the Cone of Economy method and classification system. Dr. Haddas previously worked at the Texas Back Institute as the Program Director and is currently an Executive Committee Member of the North American Spine Society.

The new contract investigates the capacities of dorsaVi's technology, which the company believes will confirm its position as a leading provider of wearable sensor devices.

¹ Assumes an A\$:US\$0.67 exchange rate.

Dr Andrew Ronchi, dorsaVi's Chief Executive Officer, commented:

"We are extremely proud to be working with such a well-respected and widely regarded institution. We are humbled to be working with Assistant Professor and Director Haddas, who is one of the leading experts in the spinal motion industry, and whose research is at the forefront of the sector. I am excited that our technology will help generate new insights to patterns of movement and potentially improve outcomes for patients with spinal conditions. We will continue to strive to work with top-tier institutions to deliver value to our shareholders."

This update has been authorised for lodgement to the ASX by the Company's Disclosure Committee.

– ENDS –

For further information about dorsaVi, please contact:

Company

Andrew Ronchi
Chief Executive Officer
+61 417 882 267
Email: ar@dorsavi.com

Investors

Dean Dribbin
Vesparum Capital
+61 3 8582 4800
Email: dorsavi@vesparum.com

About dorsaVi

dorsaVi Ltd (ASX: DVL) is an ASX listed company focused on developing innovative motion analysis device technologies for use in clinical applications, elite sports, and occupational health and safety. dorsaVi believes its wearable sensor technology enables, for the first time, many aspects of detailed human movement and position to be accurately captured, quantified, and assessed outside a biomechanics lab, in both real-time and real situations for up to 24 hours. dorsaVi's focus is on two major markets:

- **Workplace:** dorsaVi enables employers to assess risk of injury for employees as well as test the effectiveness of proposed changes to OHS workplace design, equipment or methods based on objective evidence. dorsaVi works either directly with major corporations, or through an insurance company's customer base with the aim of reducing workplace compensation and claims. dorsaVi has been used by major corporations including Sodexo, London Underground, Vinci Construction, Crown Resorts, Caterpillar (US), Monash Health, Coles, Woolworths, Toll, Toyota, Orora (formerly Amcor) and BHP Billiton.
- **Clinical:** dorsaVi is transforming the management of patients with its clinical solutions (ViMove, ViMove2 and Professional Suite) which provide objective assessment, monitoring outside the clinic and immediate biofeedback. The clinical market is broken down into physical therapy (physiotherapists), hospital in the home and elite sports. Hospital in the home refers to the remote management of patients by clinicians outside of physical therapy (i.e. for orthopaedic conditions). Elite sports refers to the management and optimisation of athletes through objective evidence for decisions on return to play, measurement of biomechanics and immediate biofeedback to enable peak performance.

Further information is available at www.dorsavi.com